Patents by Inventor Nils Aage Brünner

Nils Aage Brünner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination treatment of cancer
    Patent number: 11903927
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: February 20, 2024
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • COMBINATION TREATMENT OF CANCER
    Publication number: 20210353596
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 18, 2021
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • Combination treatment of cancer
    Patent number: 11103481
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 31, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1
    Publication number: 20210251963
    Abstract: The present invention relates to treatment of diseases characterized by elevated expression and/or activity of SRPK1 with specific SRPK1 inhibitors and to methods for identifying subjects who may benefit from such treatment.
    Type: Application
    Filed: September 6, 2019
    Publication date: August 19, 2021
    Applicant: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Jan Stenvang
  • COMBINATION TREATMENT OF CANCER
    Publication number: 20190269654
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 5, 2019
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • SELECTION OF COLORECTAL CANCER PATIENTS FOR NEO-ADJUVANT AND ADJUVENT SYSTEMIC ANTI-CANCER TREATMENT
    Publication number: 20110165577
    Abstract: The present invention relates to method for determining whether a gastrointestinal cancer patient is likely to experience a disease recurrence, said method comprising steps of determining concentration of TIMP-1 in a pre-operative plasma sample of said patient, and determining the concentration of CEA in a pre-operative body fluid sample of said patient, and evaluate whether the patient as likely to experience a disease recurrence. The present invention further provides kits for application of said methods.
    Type: Application
    Filed: June 11, 2009
    Publication date: July 7, 2011
    Inventors: Nils Aage Brünner, Hans Jørgen Nielsen
  • COMBINED METHOD FOR PREDICTING THE RESPONSE TO AN ANTI-CANCER THERAPY
    Publication number: 20110144047
    Abstract: The invention provides methods for predicting the response to a topoisomerase Il? inhibitor therapy in an individual having cancer, wherein the methods comprise the steps of determining TIMP-I DNA aberration/TIMP-1 protein aberration in combination with determining DNA aberration in TOP2A/HER2 amplicon on chromosome 17q21 including TOP2A and HER2 or aberrations of TOP2A and ErbB2 protein expression. Further provided are methods of treating cancer by using said topoisomerase Il? inhibitor therapy. The invention also comprises a kit for the application of the methods for predicting the response to a topoisomerase Il? inhibitor therapy in an individual having cancer.
    Type: Application
    Filed: May 20, 2009
    Publication date: June 16, 2011
    Applicant: DAKO DENMARK A/S
    Inventors: Nils Aage Brünner, Kristen Vang Nielsen